Information Provided By:
Fly News Breaks for December 16, 2019
AUPH
Dec 16, 2019 | 07:21 EDT
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $32 from $25 citing the company's "robustly positive" data from the Phase 3 AURORA study of voclosporin. The analyst believes voclosporin is almost assuredly to become the first treatment ever approved for lupus nephritis. He reiterates a Buy rating on Aurinia Pharmaceuticals.
News For AUPH From the Last 2 Days
There are no results for your query AUPH